STOCK TITAN

Aclaris Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced participation in two upcoming investor conferences. Dr. Neal Walker, President and CEO, will engage in a virtual fireside chat at the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET. Additionally, he will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. Virtual one-on-one meetings will also be available. Live webcasts can be accessed via Aclaris’ website, and recordings will be archived for 30 days.

Positive
  • None.
Negative
  • None.

WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferences:

  • Jefferies London Healthcare Conference. Dr. Neal Walker, the President and CEO of Aclaris, will participate in a virtual fireside chat which will be available beginning on Thursday, November 18, 2021 at 3:00 a.m. ET. Management will be available November 18th throughout the day for virtual one-on-one meetings.

  • Piper Sandler 33rd Annual Virtual Healthcare Conference. Dr. Walker will participate in a virtual fireside chat which will be available beginning on Monday, November 22, 2021 at 10:00 a.m. ET. Management will be available December 1st throughout the day for virtual one-on-one meetings.

A live webcast of each fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. Each webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Contact

investors@aclaristx.com


FAQ

When will Aclaris participate in the Jefferies London Healthcare Conference?

Aclaris will participate in the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET.

What is the date of Aclaris' participation in the Piper Sandler Virtual Healthcare Conference?

Aclaris will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET.

How can I access Aclaris' virtual fireside chats?

You can access Aclaris' virtual fireside chats through the 'Events' page in the 'Investors' section of their website.

What is the focus of Aclaris Therapeutics?

Aclaris Therapeutics focuses on developing novel drug candidates for immuno-inflammatory diseases.

Will there be one-on-one meetings after the investor conferences?

Yes, Aclaris management will be available for virtual one-on-one meetings on November 18 and December 1.

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

ACRS Rankings

ACRS Latest News

ACRS Stock Data

201.43M
71.43M
2.66%
78.17%
1.95%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States of America
WAYNE